Pharmacies should ensure appropriate monitoring procedures are in place to prevent contamination and exposure.
Pharmacy Times® commits to incorporating DEI concepts into our coverage and focusing on social determinants of health (SDOH).
Seventeen percent work in hospital settings, including compounding, inpatient, medication reconciliation, and outpatient areas.
There are 3 PARP inhibitors that are FDA approved in multiple settings of ovarian cancer.
Managing transitions of care is vital to discontinue use of unnecessary drugs and minimize medication errors.
Tapinarof is a first-in-class topical steroid-free aryl hydrocarbon receptor antagonist intended to mitigate the symptoms of plaque psoriasis.
With National Pharmacy Technician Day 2021 on October 19, AAPT Special Projects Team offers a Scavenger Hunt to celebrate this special day and the pharmacy technicians who work hard to add value to their profession.
Implement technology solutions, initiate clinical services, and shift to a proactive mindset, Michele Belcher says.
The pharmacist is the last barrier between a patient and a drug, which is why it's critical for pharmacists to check for allergies, potential drug interactions, patient understanding of how to use the drug, and whether the prescription is appropriate for the diagnosis.
Pharmacy workflow changes in the preparation of chemotherapy products can reduce patient chair time.
Properly implemented CGMP should not be seen as a regulatory burden but a remedy to poorly compounded drugs.
TXNIP inhibition could prevent beta cell loss and protect beta cell function to potentially contribute to diabetes management and its complications.
As practices have gained experience in the post-COVID-19 environment, health care professionals have found innovative ways to work around many of the obstacles the pandemic presents.
But meeting regulatory requirements may entail a great deal of financial expertise and time.
They should consider many factors and use clear guidance on predicting phenotypes from genotypes to intervene optimally based on specific drug-gene interactions.
Case studies address questions about a patient with type 2 diabetes and a patient who is curious about nicotine replacement therapy.
Patient-centric models of medication delivery that provide cost, transparency, convenience, and accessibility solutions are vital for patients to successfully navigate the current health care system.
With costs for blood and blood products continuing to rise, appropriate blood use by hospitals is more important than ever.
Since its initial approval in 2016 for urothelial carcinoma, atezolizumab has received FDA approval for an additional 5 types of carcinomas.
From a patient perspective, the lack of awareness of biosimilars is the biggest barrier to adoption.
The entire pharmacy profession and all those interested in medication safety need to coalesce around the need for systemic change in community pharmacy workplace environments.
Many pharmacies and safety-net providers were preparing for the long-anticipated transition from Medicaid managed care to fee-for-service (FFS)—known as the carve-out—that was set to take effect on May 1, 2021.
Biomarkers are commonly used by physicians to assist in the earlier diagnosis of some of the most common fungal diseases.
The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.
Specialty pharmacists play critical role in supporting treatment adherence.
A panel of experts comment on new therapeutic agents being developed and discuss their final thoughts on dry eye disease.
Although frontotemporal dementia is the leading cause of the disease for those under 65 years of age, far fewer people are familiar with it than with Alzheimer disease.
Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.
Frequent reassessments of therapy regimens address polypharmacy, particularly for older patients.
Concepts could be used in payer-pharmacy value-based arrangements.